ANDA and US Generic Revenue: Milestone-Based Ind AS 115 Reconciliation

A Tier 1 Indian pharmaceutical company of the scale of Lupin Ltd — the Mumbai-headquartered manufacturer with US-generic operations out of the Somerset New Jersey and Coral Springs Florida sales offices and the Aurangabad, Mandideep, and Ankleshwar manufacturing plants in India — closes its Q3 FY 2026-27 quarterly earnings walk on an ANDA pipeline of approximately 185 approved plus 145 pending Abbreviated New Drug Applications. Q3 delivers a final approval for a Paragraph IV first-to-file blockbuster whose 180-day exclusivity commences in the quarter, an exclusivity-window revenue release of approximately USD 45 million (illustrative) recognised over the exclusivity window on a per-shipment basis, and a variable-consideration constraint release of approximately USD 12 million (illustrative) from a prior-period tentative-approval milestone that transitions to highly probable on final approval. This is ANDA US generic revenue Ind AS 115 milestone reconciliation pharma at operating scale for a Tier 1 Indian US-generic exporter, and the discipline that keeps the ANDA pipeline register, the Ind AS 115 constraint accounting under paragraphs 56 to 58, the 180-day exclusivity revenue recognition, the India-US DTAA Article 7 business-income treatment, the Section 54(3) IGST export refund cycle, and the Ind AS 21 forex translation walk simultaneously clean is what separates a US-generic exporter whose quarterly earnings release runs on schedule from one that spends the following quarter re-stating the exclusivity-window revenue or defending a Section 271 addition on a mis-recognised milestone.

Quick reference

The reconciliation in one paragraph

An Indian pharma US-generic exporter runs a six-surface reconciliation cascade across the ANDA lifecycle. Surface one is the ANDA pipeline register — every ANDA keyed to its reference listed drug, patent certification category, and the five milestone dates (submission, notice-of-suit, tentative approval, final approval, 180-day exclusivity window). Surface two is the Ind AS 115 revenue-recognition state for each ANDA — constrained pre-final-approval, released on constraint-lift when the milestone is highly probable, point-of-sale recognition at shipment for commercial supply, per-shipment recognition during the 180-day exclusivity window. Surface three is the gross-to-net reduction stack — Medicare Part D coverage-gap discount, Medicaid rebates, Federal Supply Schedule pricing, commercial payer rebates, chargebacks against wholesaler contract prices, wholesaler stocking allowances, and the historical returns provision — all applied per Ind AS 115 variable-consideration principles. Surface four is the Ind AS 21 forex translation walk — USD-denominated receivables translated at each reporting-date closing spot rate, exchange differences to profit and loss, realisation on AD Category-I bank credit against FIRC / BRC. Surface five is the Section 54(3) IGST export refund cycle — accumulated ITC on APIs, excipients, packaging, and services claimed via quarterly GST RFD-01 filing per the Rule 89(4) formula, reconciled against DGFT shipping-bill and FIRC / BRC registers. Surface six is the India-side income-tax treatment — India-USA DTAA Article 7 business-profits taxable in India only for the no-PE direct-sale case, with Section 195 governing only the reverse leg (payments to US non-resident service providers such as patent counsel or CGMP remediation consultants). Each surface is a distinct reconciliation with its own audit trail from FDA milestone event to accounting entry to statutory audit walk.

What the scenario looks like in India — the illustrative persona

The ANDA-holding Indian pharmaceutical universe is a defined applicant pool. Tier 1 US-generic exporters include Sun Pharmaceutical Industries (Halol, Dadra, Karkhadi historical inspections and Halol as the strategic US-generic plant), Dr Reddy’s Laboratories (Bachupally, Bollaram, and the Cuernavaca Mexico facility feeding the US market), Aurobindo Pharma (multiple US-market injectable and oral solid dose plants), Lupin (Somerset New Jersey and Coral Springs Florida US-side sales offices supporting the Aurangabad, Mandideep, and Ankleshwar Indian manufacturing plants), Cipla (Goa and Kurkumbh Indian plants supporting the InvaGen US-side subsidiary since the 2016 acquisition), Zydus Lifesciences (Moraiya and Ahmedabad plants historically the US-generic backbone), Glenmark Pharmaceuticals (Halol, Baddi, and the Monroe New Jersey US-side plant), and Torrent Pharmaceuticals (Indrad Gujarat plant with a growing US-generic segment). Tier 2 US-generic exporters include Alkem Laboratories, Ipca Laboratories, Ajanta Pharma, Natco Pharma (well-known for its Paragraph IV first-to-file successes in oncology), Strides Pharma Science, Granules India, Laurus Labs (transitioning from API-only into finished dosage form ANDA filings), and JB Chemicals.

For the illustrative worked example in this article, we take a Tier 1 Indian US-generic exporter at the scale of Lupin Ltd — approximately 185 approved and 145 pending ANDAs, Somerset New Jersey and Coral Springs Florida US-side sales offices, and an Indian manufacturing footprint across Aurangabad, Mandideep, Ankleshwar, Goa, and Pithampur. The persona is illustrative; specific ANDA pipeline numbers, the identity of a Q3 FY 2026-27 Paragraph IV blockbuster, and the exclusivity-window revenue figure are not the subject of speculative recomputation here. The point of the persona is the reconciliation surface, not the identity of any specific real Indian ANDA applicant.

The geographic reconciliation footprint is bi-national: the Indian manufacturing side runs through Aurangabad, Mandideep (Bhopal outskirts, Madhya Pradesh), Ankleshwar (Gujarat), Goa, and Pithampur (Madhya Pradesh); the US commercial side runs through Somerset New Jersey (the corporate-owned Coral Springs Florida sales office and warehousing operation), the McKesson National Distribution Center in Aurora Colorado, the Cardinal Health National Logistics Center in Groveport Ohio, and the AmerisourceBergen distribution centers across the US. Every ANDA-covered generic unit exported from an Indian port (Nhava Sheva, Mundra, JNPT, Chennai) touches the DGFT shipping-bill register, the FIRC / BRC realisation cycle, the GST RFD-01 quarterly refund cycle, and the Ind AS 21 forex translation walk on the India side, and hits the wholesaler chargeback processing, the Medicaid rebate quarterly filing, the Medicare Part D coverage-gap reconciliation, and the returns processing cycle on the US side. Both sides feed the same Ind AS 115 revenue-recognition entry.

The regulatory overlay — Section 505(j), Ind AS 115 paragraphs 56 to 58, India-US DTAA Article 7, Section 54(3)

Four regulatory anchors govern the ANDA revenue cycle and each maps to a specific reconciliation surface.

Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) is the statutory framework for the Abbreviated New Drug Application. An ANDA applicant relies on the safety and effectiveness data of the reference listed drug (RLD) — the innovator’s already-approved New Drug Application — and demonstrates bioequivalence rather than repeating full clinical trials. Section 505(j)(2)(A)(vii) requires the applicant to certify against each unexpired patent listed for the RLD in the FDA Orange Book: Paragraph I (no patent listed), Paragraph II (patent expired), Paragraph III (approval sought after patent expiry), or Paragraph IV (patent invalid, unenforceable, or not infringed). A Paragraph IV Certification is a patent challenge that triggers a notice-of-suit obligation to the patent holder; on receipt of the notice, the patent holder has 45 days to file suit, and if suit is filed within that window, the FDA imposes a 30-month stay on final ANDA approval under Section 505(j)(5)(B)(iii). The first Paragraph IV applicant to submit a substantially complete ANDA — the first-to-file — is eligible for 180 calendar days of marketing exclusivity under Section 505(j)(5)(B)(iv), during which no subsequent Paragraph IV ANDA for the same drug may receive final approval. Tentative approval is granted where the ANDA meets all substantive review requirements but is subject to a delaying factor (the 30-month stay or a pending patent expiry); final approval is granted when the delaying factor resolves and commercial marketing may commence.

Ind AS 115 (Revenue from Contracts with Customers) paragraphs 56 to 58 govern the variable-consideration constraint. Paragraph 56 provides that an entity shall include in the transaction price some or all of an amount of variable consideration only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Paragraph 57 requires the entity to assess both the likelihood and the magnitude of the revenue reversal. Paragraph 58 lists factors that could increase the likelihood or magnitude — the amount is highly susceptible to factors outside the entity’s influence, the uncertainty is not expected to be resolved for a long period of time, the entity’s experience with similar contracts is limited, the entity has a practice of offering a broad range of price concessions, or the contract has a large number of possible consideration amounts. Every one of these factors applies with force to ANDA pre-commercial milestones — the outcome is outside the applicant’s influence (FDA review is the deciding factor), the uncertainty may not resolve for years (a Paragraph IV suit and its appeals can run five to seven years), the ANDA applicant’s experience with a specific compound may be limited to a single application. The default treatment is that ANDA development-phase milestones (patent-challenge win, tentative approval, final approval where they carry contingent milestone-fee entitlements under a US-side licensing arrangement) are constrained and no revenue is recognised until the milestone is achieved. The reconciliation failure-mode analysis for India methodology treats the pre-commercial constraint decision as a specific control point with a documented paragraph-56-to-58 memo per milestone.

Article 7 of the India-USA Convention for the Avoidance of Double Taxation provides that business profits of an Indian enterprise are taxable in India only, unless the enterprise carries on business in the USA through a permanent establishment (PE) situated therein. For an Indian ANDA applicant that manufactures the generic product in India, ships FOB India to a US wholesaler under a direct-sale arrangement without a US PE, and receives payment in USD through an AD Category-I authorised dealer bank into an EEFC or normal export receivable account, the US-generic business income is Article 7 business profits taxable in India only. US-side withholding under Internal Revenue Code Section 1441 generally does not apply to no-PE business income under Article 7 for a treaty resident with proper Form W-8BEN-E documentation on file with the US withholding agent. India taxes the income under normal provisions with the appropriate rate — 22 percent under Section 115BAA if opted-in (which requires forfeiture of Section 35(2AB) weighted deduction, a trade-off treated in the PLI pharma Rs 15,000 crore eligibility incremental sales reconciliation cornerstone) or the regular corporate rate. Where the Indian applicant has a US subsidiary (a US Inc. that acts as the marketing arm and imports from the Indian parent), the intra-group arrangement is a separate transfer-pricing surface under Section 92CA and US Section 482 regulations — distinct from the direct-sale case treated here.

Section 54(3)(i) of the CGST Act 2017 permits refund of unutilised input tax credit accumulated on account of zero-rated supplies made without payment of tax. ANDA-covered generic formulations exported from India to the USA under a Letter of Undertaking (LUT) are zero-rated supplies under Section 16(1)(a) and Section 16(3) of the IGST Act 2017. The Indian ANDA applicant accumulates ITC on APIs (18 percent under HSN Chapter 29 or 30 per the API vs formulation HSN 2941 / 3003 / 3004 reconciliation guide), excipients, primary and secondary packaging, and services. Because the export supply carries zero output IGST when made under LUT, the accumulated ITC has no output liability to offset and is refundable via GST RFD-01 within two years from the relevant date. The refund proportion is computed per Rule 89(4) CGST Rules 2017 formula; the cycle is quarterly-eligible. For a pure-play US-generic exporter the ratio tends to 100 percent of accumulated ITC. The refund pack reconciles to the FIRC / BRC realisation register from the AD Category-I bank and the DGFT shipping-bill register. This export zero-rated variant of Section 54(3) is distinct from the domestic inverted-duty variant treated in the rule 89(5) inverted-duty refund pharma formulations complete guide — the same section, two different sub-clauses, two different reconciliation surfaces.

A worked example — a Tier 1 Indian US-generic exporter at Q3 FY 2026-27 close

Illustrative — the following figures represent the operating pattern of a Tier 1 Indian ANDA-holding US-generic exporter of the scale of Lupin Ltd. Public disclosures do not reveal per-ANDA milestone accounting, per-quarter exclusivity-window revenue, or the identity of a specific Q3 FY 2026-27 Paragraph IV blockbuster; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant.

A Tier 1 Indian US-generic exporter closes Q3 FY 2026-27 (October to December 2026) with three ANDA-level events:

Event A — a Paragraph IV first-to-file ANDA for a blockbuster cardiovascular generic receives FDA final approval on 15 October 2026 following expiry of the 30-month stay and a court decision in the applicant’s favour on the underlying patent challenge. First commercial marketing commences 20 October 2026, triggering the 180-day exclusivity window that runs through 18 April 2027. Q3 shipments to McKesson, Cardinal Health, and AmerisourceBergen at exclusivity-window pricing generate gross invoiced revenue of approximately USD 52 million. Applying the gross-to-net stack (chargebacks estimated at 8 percent, Medicaid rebates at 3 percent, commercial rebates at 2 percent, wholesaler stocking allowances at 1 percent, returns provision at 1 percent — aggregate 15 percent), net revenue recognised under Ind AS 115 point-of-sale for each shipment in Q3 is approximately USD 44.2 million. At the average Q3 exchange rate of INR 84.50 per USD, that translates to INR 373.5 crore. The exclusivity-window revenue is NOT front-loaded on the 20 October first-commercial-marketing date; it is recognised shipment-by-shipment across the 90 days of Q3 that fall within the exclusivity window.

Event B — a prior-period tentative approval milestone under an out-license arrangement with a US marketing partner for a different generic (a respiratory device combination product) transitions to final FDA approval on 10 December 2026. The contract provided for a USD 12 million contingent milestone fee on final approval. Under Ind AS 115 paragraph 56-58, this milestone was constrained through the tentative-approval stage (final approval was not highly probable given the CGMP remediation history of the manufacturing plant, which had been under a Form 483 observation cycle documented in the USFDA Form 483 remediation cost accounting treatment guide framework). Final approval on 10 December resolves the uncertainty; the constraint lifts on 10 December and the USD 12 million is recognised in Q3 profit and loss. At the 10 December spot rate of INR 84.40 per USD, that translates to INR 101.3 crore of Q3 revenue release. This is a one-time event, not a per-shipment recognition — it is a constrained-milestone release.

Event C — commercial supply of approximately 30 other ANDA-covered generic products in the pipeline (post-exclusivity, in the mature-generic-price-erosion phase where multiple ANDA competitors are in the market) generates aggregate Q3 gross invoiced revenue of approximately USD 85 million. Applying the mature-generic gross-to-net stack (chargebacks 12 percent, Medicaid rebates 4 percent, commercial rebates 3 percent, wholesaler stocking allowances 1 percent, returns provision 2 percent — aggregate 22 percent), net revenue recognised under Ind AS 115 point-of-sale is approximately USD 66.3 million. At the average Q3 exchange rate of INR 84.50 per USD, INR 560.2 crore.

Aggregate Q3 US-generic revenue is illustratively:

On the accounting side, the Ind AS 21 translation walk at 31 December 2026 quarter-end takes the USD-denominated receivables (approximately USD 78 million outstanding across the three revenue streams net of Q3 realisations) at the 31 December closing spot rate of INR 84.60 per USD and posts the exchange difference against the average-rate-recognised revenue to the forex fluctuation line in profit and loss. The AD Category-I bank realisation for Q3 shows FIRC / BRC-matched inflows of approximately USD 108 million against Q3-invoiced amounts — the timing gap between invoice and realisation is the standard US-wholesaler payment cycle of 45 to 60 days. The GST RFD-01 filing for Q3 (typically filed in January 2027 for the October-December 2026 quarter) claims accumulated ITC refund on the Rule 89(4) formula against the zero-rated turnover of INR 1,035 crore, generating an expected refund of approximately INR 42 crore on the accumulated APIs / excipients / packaging / services ITC pool.

On the India-side tax provisioning schedule, the entire USD-generic income of INR 1,035 crore is treated as Article 7 business profits taxable in India only (the applicant has no US PE — the Somerset New Jersey office is a liaison and warehousing function without contract-conclusion authority, and the US wholesalers act as independent distributors, not dependent agents). Under Section 115BAA at 22 percent (assuming the applicant is under the concessional regime), the tax provision is approximately INR 228 crore before foreign tax credit for any US-side taxes withheld. Section 195 is not triggered on the wholesaler receipts (they are non-resident payers to the Indian applicant, not Indian payers to a non-resident); Section 195 is triggered only on the reverse leg — Q3 payments the applicant made to US patent counsel firms (illustratively USD 2.5 million on the Paragraph IV litigation defence) for which India-USA DTAA Article 15 (Independent Personal Services) or Article 12 (Fees for Included Services) governs the withholding rate.

Common reconciliation breakages

Six breakages recur across ANDA revenue reconciliation runs, and each maps to a specific control failure.

• Exclusivity-window revenue front-loaded on first-commercial-marketing date rather than recognised shipment-by-shipment. Applicants that book a lump-sum exclusivity revenue on Day 1 of the 180-day window (or worse, on the final approval date before first-commercial-marketing) violate Ind AS 115 point-of-sale recognition for goods sold on a per-shipment basis. The correct treatment is that revenue is recognised as each unit ships to the US wholesaler at the invoiced price with gross-to-net reduction — the exclusivity window is a pricing event, not a lump-sum-recognition event. The statutory audit picks up this error at the SEC-15 quarter-end walk-through if the revenue is booked before the corresponding invoiced shipment appears in the sales ledger.

• Variable-consideration constraint prematurely released on tentative approval. An applicant that recognises a contingent milestone-fee on tentative approval (rather than waiting for final approval or a highly-probable state) violates Ind AS 115 paragraphs 56 to 58. Tentative approval is by definition subject to a delaying factor (typically the 30-month stay or a pending patent expiry); the uncertainty about the delaying factor’s resolution has not been resolved. Premature recognition drives a subsequent reversal if the final approval does not follow. The reconciliation discipline is that the constraint memo per milestone must survive statutory audit scrutiny — the memo must document the delaying factor, the applicant’s assessment of resolution likelihood, and the paragraph-58 factors that keep the constraint in force.

• Gross-to-net reduction stack under-estimated on Q1 of exclusivity window. The exclusivity-window gross-to-net stack is materially different from the mature-generic stack — chargebacks are lower (because there is only one generic competitor, so wholesalers negotiate less aggressively), Medicaid rebates follow the URA (Unit Rebate Amount) formula that penalises the exclusivity-window pricing spread (best-price-plus-CPI penalty under 42 U.S.C. 1396r-8), commercial rebates depend on the specific PBM contract portfolio. Applicants that apply the mature-generic gross-to-net percentage to exclusivity-window shipments over-recognise net revenue in Q1 of exclusivity and then correct in Q2 or Q3 through a change in accounting estimate — a preventable earnings-quality flag.

• India-US DTAA Article 7 treatment gap where the applicant has a US subsidiary. An applicant that runs a US-marketing-arm subsidiary (a US Inc. that imports from the Indian parent and distributes to US wholesalers) is not in the Article 7 no-PE direct-sale case — the applicant has a US taxable presence through the subsidiary, and the intra-group transfer from India to the US Inc. is a Section 92CA specified international transaction subject to Rule 10D transfer-pricing documentation and US Section 482 review. Applicants that treat the intra-group case as if it were the direct-sale case (applying Article 7 without a transfer-pricing analysis) create both an Indian TP exposure and a US-side subsidiary tax exposure. The reconciliation discipline is that the US-side commercial arrangement flag (direct-to-wholesaler / US-subsidiary-import / licensed-out) must drive distinct accounting and tax treatments.

• Section 54(3) IGST refund claim mis-computed under Rule 89(4). The Rule 89(4) formula is (Turnover of zero-rated supply of goods + Turnover of zero-rated supply of services) x Net ITC / Adjusted Total Turnover. Applicants that use gross turnover (before returns) rather than net turnover, or that fail to exclude a domestic sale to a related party from Adjusted Total Turnover, or that fail to include a legitimate zero-rated service export (a US-side clinical study service provided from India) in the numerator, mis-compute the refund. The refund cycle exposes the mis-computation through the CGST officer’s Rule 92 processing queries.

• Ind AS 21 forex translation gap between reporting-date translation and bank realisation. Applicants that translate USD-denominated receivables at the reporting-date closing rate but book the forex fluctuation only on realisation (rather than at each reporting date) create a Q-end mis-statement. The Ind AS 21 discipline is that the translation happens at each reporting date whether or not the receivable has been realised, with the exchange difference to profit and loss. The bank realisation is a separate event that settles the receivable at the realisation-date spot rate; the difference between the previous reporting-date translation and the realisation-date rate is the second forex event, also to profit and loss. Terra Insight’s Reconciliation Playbook monthly close framework treats the Ind AS 21 translation as a specific month-end control point with documented Q-end and realisation-event journal entries.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the ANDA pipeline register from the applicant’s regulatory affairs system (with milestone dates from the FDA Orange Book and press-release stream), the SAP FI or Oracle Fusion sales ledger by SKU for the US-generic segment, the wholesaler chargeback processing feed (McKesson, Cardinal Health, AmerisourceBergen), the Medicaid Drug Rebate Program (MDRP) quarterly URA computation, the AD Category-I bank realisation register with FIRC / BRC-matched inflows, the DGFT shipping-bill register, and the RBI reference rate feed for Ind AS 21 translation — and produces a per-ANDA revenue-recognition walk that ties FDA milestone event to Ind AS 115 constraint decision or point-of-sale entry to Ind AS 21 forex translation to bank realisation. The platform enforces the Ind AS 115 paragraph 56-58 constraint discipline (no revenue recognition on pre-commercial milestones unless highly probable), generates the exclusivity-window per-shipment recognition schedule with the exclusivity-specific gross-to-net stack, drives the quarterly GST RFD-01 export refund pack per Rule 89(4), and feeds the India-USA DTAA Article 7 business-income treatment into the entity’s tax provisioning schedule. Match rate improvement of 51 to 88 percent on the shipment-to-invoice-to-realisation walk and the wholesaler-chargeback-to-net-revenue reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier 1 Indian US-generic exporter running an ANDA pipeline of 100-plus approved products rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The ANDA revenue discipline in this cornerstone sits alongside the PLI Pharma scheme claim cycle for a Category 1 applicant with a US-generic pipeline — the PLI pharma Rs 15,000 crore eligibility incremental sales reconciliation walk covers the Ind AS 20 grant-recognition side while this ANDA cornerstone covers the Ind AS 115 revenue-recognition side; a Tier 1 Indian US-generic exporter typically runs both simultaneously with the two grant/revenue tracks reconciling into a single quarterly earnings walk. The USFDA remediation cost accounting for a plant under a Form 483 or Warning Letter is treated in the USFDA Form 483 remediation cost accounting treatment guide; a plant under active remediation carries a specific Ind AS 37 provision exposure and can also carry a specific Ind AS 115 revenue-recognition constraint for import-alert-affected products (an ANDA-holder whose Warning Letter has escalated to an Import Alert 66-40 or 89-08 loses US-market access for the affected plant and must reverse in-transit revenue). The CGMP remediation posture links to the loan-licensing manufacturing and pharma CDMO reconciliation guide where the ANDA is filed against a plant owned by a third-party contract manufacturer under a US-side outsourcing arrangement, and to the Section 35(2AB) weighted deduction pharma R&D reconciliation guide for the pre-ANDA R&D spend accounting on the Indian tax side. The zero-rated export refund cycle links back to the rule 89(5) inverted-duty refund pharma formulations complete guide for the domestic inverted-duty variant of Section 54(3). The methodology framework for structuring the ANDA revenue walk as a controlled reconciliation surface is set out in Terra Insight’s reconciliation failure-mode analysis for India pillar. The commercial pillar for the entire pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

The five FAQs below address the operational questions pharma controllers, US-generic segment finance leads, and statutory auditors ask most often when reconciling the ANDA milestone lifecycle against Ind AS 115 revenue recognition and the India-US DTAA business-income treatment.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024